Breaking Finance News

BidaskClub upgraded Achaogen Inc (NASDAQ:AKAO) to Buy in a report released today.

BidaskClub has upgraded Achaogen Inc (NASDAQ:AKAO) to Buy in a report released on 7/08/2017.

Previously on Thursday June 15, 2017, HC Wainwright reported on Achaogen Inc (NASDAQ:AKAO) increased the target price from $0.00 to $29.00. At the time, this indicated a possible upside of 0.31%.

Yesterday Achaogen Inc (NASDAQ:AKAO) traded -0.24% lower at $23.80. The company’s 50-day moving average is $21.17 and its 200-day moving average is $22.10. The last closing price is up -24.64% from the 200-day moving average, compared to the S&P 500 which has increased 0.05% over the same time period. 638,947 shares of the stock traded hands, down from an average trading volume of 823,589

See Chart Below

Achaogen Inc (NASDAQ:AKAO)

With a total market value of $0, Achaogen Inc has with a one year low of $3.68 and a one year high of $27.79 .

A total of 6 equity analysts have released a ratings update on AKAO. One equity analyst rating the company a strong buy, three equity analysts rating the company a buy, two equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $14.17.

Brief Synopsis About Achaogen Inc (NASDAQ:AKAO)

Achaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Plazomicin is an intravenous aminoglycoside antibiotic. The Company has developed plazomicin by chemically modifying sisomicin, a naturally occurring aminoglycoside, in order to overcome common aminoglycoside resistance mechanisms. The Company has a portfolio of small molecule and antibody programs. The Company's Early Development programs include C-Scape and LpxC.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.